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Background: Probiotics have currently been widely used in patients undergoing various types of surgeries and
improved their clinical outcomes, while data in pediatric cardiac surgery have been lacking. We investigated the
safety and effects on the intestinal microbiota of the probiotic Bifidobacterium breve in neonates undergoing
surgery for congenital heart disease.
Methods: This pilot, randomized study was performed in a single-center, university hospital-based pediatric intensive
care unit (PICU). Twenty-one neonates undergoing surgery for congenital heart disease at >7 days after birth were
randomly allocated to two groups: group A received 3 × 109 colony-forming units (CFU)/day of enteral B. breve strain
Yakult (BBG-01), which was started 1 week before and terminated 1 week after surgery (n = 10), and group B did not
receive BBG-01 (n = 11).
Results: The characteristics of the patients were similar in both groups. The postoperative days until fulfillment of the
criteria for discharge from the PICU tended to be fewer in group A (8 [7–8] days) than in group B (9 [8–14] days)
(p = 0.10). Likewise, the postoperative days to enteral nutrition or achievement of caloric goal tended to be
fewer in group A than in group B. The Bifidobacterium in fecal samples after initiating BBG-01 in group A were
significantly higher in number than that in group B. Enterobacteriaceae were significantly fewer in group A than
in group B immediately (7.0 [3.9–7.7] vs. 8.5 [8.0–9.1] log10 cells/g) and 1 week (7.7 [7.0–8.1] vs. 9.3 [8.6–9.5] log10
cells/g) after surgery (p < 0.05 for both comparisons). The number of Pseudomonas after 1 week was significantly
lower in group A than in group B (p = 0.04). The concentrations of total organic and acetic acids were also significantly
higher in group A than in group B. The postoperative course was uncomplicated and all neonates were discharged
alive from the PICU.
Conclusions: The perioperative administration of a probiotic to neonates undergoing surgery for congenital heart
disease was safe and significantly improved their intestinal environment. The positive effects of this treatment on
clinically significant outcomes remain to be investigated.
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Surgery for congenital heart diseases is performed in neo-
nates worldwide with high success rates [1]. Infections and
acute organ failure remain important complications
and causes of reoperation, prolonged hospitalization, and
intensive care, which significantly increase the postoperative* Correspondence: shime@koto.kpu-m.ac.jp
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corrective or palliative cardiac surgery are at increased risk
of mesenteric hypoxia due to oxygen desaturation and
low cardiac output. These patients often receive antimi-
crobials for prophylactic or non-prophylactic indications.
Moreover, the incidence of delayed enteral feeding
due to respiratory or cardiovascular instability is high
[4]. These factors, alone or in combination, may disrupt
the intestinal microbiota and function of the intestinal
barrier, followed by bacterial translocation and associated
disorders [5,6].l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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to a host when administered in sufficient amounts [7].
They have been widely used in critically ill [8,9] or cancer-
ous patients undergoing surgery [10,11] and allegedly im-
proved their clinical outcomes. The beneficial effects are
likely due to an enhanced immune response to pathogens,
competition for nutrition with pathogenic bacteria, im-
proved immunologic function of the intestinal barrier, and
a downregulation of proinflammatory cytokines [12,13].
Despite the putative therapeutic effects they confer to
neonates at risk of intestinal failure, studies of probiotics
in neonates undergoing neonatal surgery for congenital
heart disease are scarce [14]. Therefore, in this pilot study,
we examined the effects of the perioperative administra-
tion of probiotic bacteria, Bifidobacterium breve [15-17],
on the intestinal microbiota and the clinical outcomes of
neonates who underwent cardiac surgery.
Methods
Patients
This study was approved by the ethics committee for
clinical investigation of Kyoto Prefectural University,
School of Medicine (Kyoto, Japan). Between April 2007
and April 2010, neonates admitted to our pediatric
intensive care unit (PICU) and scheduled to undergo
cardiac surgery between 1 to 2 weeks after birth were
enrolled in this study. After excluding patients who
were expected to undergo surgery within 7 days (n = 3)
or who had received mechanical ventilation (n = 4), we
enrolled 24 patients for randomized analysis. Of those,
data from 21 patients who actually underwent surgery
after over 7 days of age were finally analyzed (Figure 1).Figure 1 Flow diagram. A total of 21 patients were finally analyzed. PICUA signed informed consent was obtained from their
parents. The patients were randomly assigned to group
A, who received 3 × 109 colony-forming units (CFU)/
day of enteral B. breve strain Yakult (BBG-01), which
was administered starting 1 week before and ending
1 week after surgery (n = 10), and group B, who did not
receive BBG-01 (n = 11). BBG-01 was a live, freeze-dried
probiotic, containing 109 bacteria/g, and was generously
provided by Yakult Central Institute for Microbiological
Research under a written agreement. We chose the dose
on the basis of previous pediatric studies, where BBG-01
was administered in doses ranging between 1 × 109 [15]
and 4 × 109 CFU/day [17].
All patients received prophylactic intravenous cefazolin,
25 mg/kg every 8 h, for 24 h, started immediately before
the surgical incision. Enteral breast or artificial milk was
fed upon the decision of the attending physicians, begin-
ning with 1–2 ml/kg every 3 h, and increased by 2 ml/kg
with each feeding to a target of 8 ml/kg every 3 h, if the
gastric residuals were <50% of the administered dose and
in the absence of vomiting or diarrhea.
Clinical endpoints
We measured the rates of postoperative infections and
the survival rate at the time of discharge from the PICU.
We also counted the postoperative days until (a) the
criteria for discharge from the PICU were fulfilled, (b)
initiation of or candidacy for milk feeding, and (c)
spontaneous defecation. The criteria for discharge from
the PICU were the observation of stable vital signs and
freedom from all indwelling lines, including the pericardial
drains.pediatric intensive care unit.
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Sample collection
Fecal samples were collected (1) before the administration
of BBG-01, (2) immediately before the operation, 1 week
after the start of BBG-01 administration, (3) immediately
after surgery, and (4) 1 week after the operation. For
the sampling of the postoperative samples, we allowed
delay <48 h in cases of lacking defecation. Immediately
after defecation, the samples were weighed and suspended
in nine volumes of RNAlater® (Ambion Inc., Austin, TX,
USA), an RNA stabilization solution, and then incubated
for 10 min at room temperature.Isolation of total RNA or total DNA
For RNA or DNA stabilization, 200 μl of fecal hom-
ogenate was added to 1 ml of sterilized phosphate buf-
fer solution and then centrifuged at 5,000 g for 10 min.
The supernatant was discarded and the pellet was stored
at −80°C until used for the extraction of RNA or DNA.
Methods described elsewhere were used to isolate RNA
[18] and DNA [19]. Finally, the nucleic acid fraction was
suspended in 1 ml of nuclease-free water (Ambion Inc.).Bacterial count
A standard curve was generated using reverse transcrip-
tion-quantitative polymerase chain reaction (RT-qPCR)
data, using the threshold cycle, the number of cycles
when threshold fluorescence was reached, and the
corresponding cell count, which was determined micro-
scopically with 4,6-diamidino-2-phenylindole staining
(Vector Laboratories, Burlingame, CA, USA) for the
dilution series of the standard strains described elsewhere
[18]. To determine the number of bacteria present in the
samples, three serial dilutions of an extracted RNA sample
were used for the RT-qPCR, and the threshold cycle
values in the linear range of the assay were applied to the
standard curve generated in the same experiment, to ob-
tain the corresponding bacterial cell count in each nucleic
acid sample, which was then converted to the number of
bacteria per sample. The specificity of the RT-qPCR assay
using group- or species-specific primers was determined
as described previously [18]. The quantitative analysis of
B. breve strain Yakult has been described elsewhere [19].
The detection limits were as follows: 5.0 cells/g for the
Clostridium coccoides group, Clostridium leptum sub-
group, Bacteroides fragilis group, Bifidobacterium, Atopo-
bium cluster, and Prevotella, 2.1 cells/g for Clostridium
perfringens, 2.1 cells/g for total Lactobacillus, 3.9 cells/g
for Enterobacteriaceae, 3.9 cells/g for Enterococcus, 3.6
cells/g for Staphylococcus, 2.9 cells/g for Pseudomonas,
and 6.0 cells/g for B. breve strain Yakult. We treated
data below the detection limit as each detection limit
for statistic analysis.Fecal organic acid concentrations and pH
A sample of the homogenized stool was isolated, weighed,
mixed with 0.15 M perchloric acid in a fourfold volume,
and reacted for 12 h at 4°C. The mixture was centrifuged
at 20,000 g for 10 min at 4°C, and the supernatant was
filtered with a 0.45-μm membrane filter (Millipore Japan,
Tokyo, Japan) and sterilized. The concentration of organic
acids in the sample was measured using a Waters high-
performance liquid chromatography system and 432
Conductivity Detector (Waters Co., Tokyo, Japan) and a
Shodex Rspack KC-811 column (Showa Denko, Tokyo,
Japan) [11,16]. We prepared a standard mixed solution
containing 1 to 20 mM of succinic, lactic, formic, acetic,
propionic, isobutyric, butyric, isovaleric, and valeric
acids and calculated the concentrations of these or-
ganic acids based on the standard curve. The stool pH
was measured by inserting the glass electrode of a D-51
pH meter (Horiba Seisakusho, Tokyo, Japan) directly
into the samples of homogenized stool. The detection
limits were as follows: 0.075 μmol/g for succinic acid,
0.2 μmol/g for lactic acid, 0.05 μmol/g for formic acid,
0.4 μmol/g for acetic acid, 0.5 μmol/g for propionic
acid, 0.55 μmol/g for butyric acid, 0.8 μmol/g for isova-
leric acid, and 0.65 μmol/g for valeric acid. We treated
data below the detection limit as each detection limit
for statistic analysis.Statistics analysis
The results are expressed as median [interquartile range
(IQR)]. Mann-Whitney’s U test was used to compare be-
tween two groups, and comparison of the time-dependent
data between two groups was performed using Wilcoxon’s
signed-rank test.Results
The mean weights, gender distributions, and risk-adjusted
congenital heart surgery (RACHS) category were similar,
while the numbers of cardiac deformity involving aortic
arch anomalies tended to be greater in group B (Table 1).
No patient suffered complications from the probiotic
administration.Clinical endpoints
No patient died or developed necrotizing enterocolitis.
One patient in group B developed an infection at the
surgical site. The criteria for postoperative discharge
from the PICU tended to be fulfilled earlier (8 [7–8]
days) in group A than in group B (9 [8–14] days) (p =
0.10; Table 2). Likewise, the mean time to (a) initiation of
or candidacy for enteral nutrition and (b) spontaneous
defecation tended to be shorter in group A than in group
B (Table 2).
Table 1 Patient characteristics and congenital diseases
Group A Group B
(n = 10) (n = 11)
Weight, kg 2.9 [2.8–3.0] 3.0 [2.9–3.1]
Males 5 (50%) 8 (73%)
Procedural times, min
Overall operation 340 [267–378] 300 [220–332]
Cardiopulmonary bypass 152 [138–200] 167 [82–190]
Anesthesia 475 [395–503] 400 [298–428]
RACHS category 4 [3–4] 4 [3–4]
Congenital anomalies
Transposition of great vessels 5 4
Interruption of the aortic arch 1 3
Double outlet right ventricle 2 0
Hypoplastic left heart syndrome 0 2
Coarctation of the aorta 2 1
Total anomalous pulmonary venous
return
0 1
Selected types of surgeries
Arterial switch 6 4
Aortic arch repair 3 4
Pulmonary arterial banding 1 1
Norwood surgery 0 1
Total anomalous pulmonary venous
return repair
0 1
RACHS risk-adjusted congenital heart surgery. Values are median [IQR] or
numbers (%) of observations. No significant differences between the groups.
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No significant differences in total numbers of fecal micro-
biota were observed between the two groups (Table 3).
The number of Bifidobacterium was significantly higher in
group A than in group B throughout the courses. BBG-01,
the probiotic administered, was isolated from the feces
in group A only (Table 3). Concordantly, the number of
Enterobacteriaceae in the log10 scale was significantly
lower in group A than in group B, both immediately
(7.0 [3.9–7.7] vs. 8.5 [8.0–9.1]) and 1 week (7.7 [7.0–8.1]
vs. 9.3 [8.6–9.5]) after surgery (p < 0.05 for both com-
parisons). The number of Staphylococcus 1 week afterTable 2 Clinical endpoints
Group A Group B p
value(n = 10) (n = 11)
Duration of MV, h 44 [18–67] 42 [19–37] 0.62
Days until
Discharge criteria fulfilled, days 8 [7–8] 9 [8–14] 0.10
Target enteral nutrition, days 5 [4–6] 6 [5–8] 0.09
Spontaneous defecation, days 2 [1–2] 2 [2–5] 0.09
MV mechanical ventilation. Values are median [IQR].surgery in the log10 scale was also significantly lower in
group A than in group B (Table 3). The number of
Pseudomonas after 1 week was significantly lower in
group A than in group B (p = 0.04).
Fecal organic acid concentration and pH
The total postoperative concentration of organic acids
was significantly higher in group A than in group B and
was significantly higher than the total concentration be-
fore initiating BBG-01 (Table 4). The significantly higher
concentrations of acetic acid in group A than in group B
both immediately and 1 week after surgery are particu-
larly noteworthy (Table 4). Also, the concentration of
acetic acid after initiating BBG-01 was significantly higher
than that before initiating BBG-01. The fecal pH before
initiating BBG-01 was significantly higher than that 1 week
after surgery. Finally, the fecal pH tended to be lower
in group A than in group B (before surgery p = 0.067,
immediately after surgery p = 0.067, 1 week after surgery
p = 0.053).
Discussion
The perioperative administration of probiotics to neonates
undergoing cardiac surgery was well tolerated and signifi-
cantly improved their fecal microbiota, expressed by a
higher detection rate of obligate anaerobe and concentra-
tion of organic acids and a lower pH. The intestinal
microbiota typically develops within 3 to 4 h after birth
and stabilizes within approximately 2 weeks. Obligate
anaerobes account for >95% of the commensal micro-
biota, with Bifidobacterium as the predominant micro-
organism [6]. As observed in this study, the microbiota in
neonates undergoing cardiac surgery may be disrupted
below the detection limit throughout the perioperative
period. By contrast, the administration of Bifidobacterium
may successfully preserve the intestinal microbiota and
decrease the presence of pathogenic Enterobacteriaceae
significantly. This is concordant with previous studies,
which found a decrease in Enterobacteriaceae after the
administration of BBG-01 to Bangladeshi children <5 years
of age [17]. The concentration of acetic acid, one of the
short-chain fatty acids, was also significantly higher in re-
cipients of BBG-01. Short-chain fatty acids are important
anions in the colonic lumen, which influence both the
morphology and function of the colonocytes, and their
increase lowers the pH, which indirectly modifies the
composition of the colonic microbiota and increases the
absorption of minerals [20]. Shin et al. have suggested that
a low pH is important to decrease the incidence of infec-
tions due to the O157 subtype of Escherichia coli [21].
These changes in the intestinal environment might con-
tribute to the trend of earlier postoperative recovery of en-
teral nutritional intake and defecation. A recent clinical
study has also shown that perioperative administration of
Table 3 Fecal microorganisms
Surgery
Before BBG Before Immediately after 1 week after
Group A Group B Group A Group B Group A Group B Group A Group B
n = 7 n = 10 n = 11 n = 10 n = 11 n = 10 n = 11
Total 9.7 [8.9–9.9] (100) NT 9.8 [9.1–10.2] (100) 9.7 [9.3–9.9] (100) 9.9 [9.5–10.6]**** (100) 9.8 [8.7–10.0] (100) 9.9 [9.5–10.1] (100) 9.8 [9.5–9.9] (100)
Obligate anaerobes
Clostridium coccoides group 8.7 [8.6–8.8] (29) NT 6.4 [6.2–7.2] (30) 7.3 [6.2–8.4] (18) 7.9 [7.3–8.4] (40) 8.6 [8.1–8.6] (27) 6.2 [6.0–6.7] (50) 8.4 [7.2–9.0] (36)
C. leptum subgroup 6.3 [6.2–6.3] (29) NT 5.6 [5.5–5.7] (20) 6.6 [6.3–7.4] (36) 6.0 [5.6–6.3] (20) 8.3 [7.8–8.8] (27) 5.9 [5.7–6.5] (30) 8.1 [7.6–8.5] (27)
Bacteroides fragilis group 9.5 [8.7–9.6] (71) NT 9.0 [8.5–9.6] (60) 9.4 [9.3–10.1] (45) 8.4 [7.0–9.3] (60) 9.3 [9.2–9.9] (45) 9.4 [8.6–9.6] (70) 9.1 [8.8–9.2] (45)
Bifidobacterium 7.0 [6.2–7.7] (42) NT 9.5 [9.0–9.8]**, *** (100) 9.0 [7.9–9.1] (27) 9.7 [9.4–10.2]**,
***, **** (100)
8.9 [8.8–9.6] (45) 9.7 [9.2–9.9]**, *** (100) 9.2 [8.9–9.6] (45)
Bifidobacterium breve Yakult <6.0 (0) NT 9.1 [8.4–9.7]**, *** (100) <6.0 (0) 9.2 [8.6–9.5]**, *** (100) <6.0 (0) 9.0 [8.9–9.3]**, *** (100) <6.0 (0)
Atopobium cluster 7.9 [7.4–7.9] (42) NT 6.2 [5.7–6.5] (30) 8.3 [8.1–8.4] (18) 6.9 [6.3–7.7] (30) 8.4 [8.2–8.6] (18) 6.7 [6.2–6.7] (30) 7.9 [7.5–8.2] (18)
Prevotella 6.2 [6.1–6.2] (29) NT 5.4 [5.3–5.5] (20) 5.2 (9) 5.1 (10) 5.7 (9) 6.4 (10) 5.6 (9)
C. perfringens <2.1 (0) NT 2.9 (10) <2.1 (0) <2.1 (0) <2.1 (0) 2.7 (10) 2.7 (9)
Facultative anaerobes
Total Lactobacillus 5.0 [5.0–5.9] (57) NT 5.4 [5.1–5.7] (20) 3.2 [2.9–3.3] (27) 4.3 [3.6–4.9] (60) 3.2 [2.7–3.3] (27) 4.7 [3.9–4.8] (60) 3.7 [3.6–3.8] (27)
Enterobacteriaceae 8.6 [8.2–8.7] (71) NT 7.5 [7.2–7.8] (60) 8.0 [7.8–8.8] (73) 7.5 [7.1–8.0]* (60) 8.5 [8.3–9.2] (82) 7.7 [7.0–8.1]*, **** (90) 9.4 [8.9–9.6]**** (91)
Enterococcus 8.7 [8.3–9.6] (71) NT 8.2 [6.7–9.0] (70) 8.6 [8.2–9.5] (82) 8.4 [7.5–9.4]**** (100) 8.5 [8.2–8.8] (100) 8.3 [8.0–8.8] (100) 8.5 [7.9–9.5] (100)
Staphylococcus 8.1 [7.2–9.1] (71) NT 6.9 [6.4–7.4] (90) 8.5 [6.3–9.0] (100) 6.2 [5.1–7.2]**** (80) 6.7 [5.5–7.2] (100) 6.3 [5.1–6.7]* (100) 7.2 [6.8–8.1] (100)
Obligate aerobes
Pseudomonas 4.3 (14) NT <2.9 (0) 3.5 [3.1–3.6] (27) 3.4 (10) 3.5 [3.5–3.5] (18) <2.9 (0)* 3.9 [3.7–4.5] (36)

















Table 4 Fecal organic acid concentrations and pH
Surgery
Before BBG Before Immediately after 1 week after
Group A Group B Group A Group B Group A Group B Group A Group B
n = 7 n = 10 n = 11 n = 10 n = 11 n = 10 n = 11
Total organic acids 21.7 [14.1–34.8] (100) NT 52.6 [29.7–64.9] (100) 31.9 [26.2–62.9] (100) 61.3 [51.5–99.8]**, *** (100) 40.7 [17.1–48.5] (100) 95.2 [61.0–105.4]*, *** (100) 48.0 [39.9–88.6] (100)
Succinic acid 6.3 [4.9–8.2] (57) NT 10.6 [8.6–14.2] (70) 16.2 [7.8–30.9] (73) 3.5 [1.3–15.0] (70) 11.2 [7.2–21.7] (45) 9.4 [1.9–15.2] (90) 3.3 [2.5–21.5] (64)
Lactic acid 10.0 [6.2–18.0] (57) NT 7.8 [3.0–15.5] (70) 4.9 [4.2–7.1] (64) 8.9 [7.2–10.8] (90) 7.3 [5.5–8.3] (45) 18.8 [5.1–27.7] (100) 14.6 [3.8–24.2] (73)
Formic acid 3.6 [2.4–4.7] (29) NT 2.6 [1.5–4.7] (60) 3.3 [2.5–6.4] (36) 5.4 [3.9–5.9] (60) 2.5 [1.5–3.4] (91) 2.2 [1.1–3.4] (50) 2.5 [1.9–3.8] (64)












Propionic acid 0.9 (14) NT 2.4 [2.0–5.0] (30) 4.4 [3.6–5.6] (36) 4.5 [2.7–6.2] (20) 3.1 [1.9–4.2] (18) 7.9 [4.5–7.9] (30) 13.3 [4.2–23.5] (36)
Butyric acid <0.55 (0) NT <0.55 (0) 0.8 (9) <0.55 (0) 3.6 [2.2–4.9] (18) <0.55 (0) 2.9 [1.7–4.2] (18)
Isovaleric acid <0.8 (0) NT <0.8 (0) 7.0 (9) <0.8 (0) <0.8 (0) <0.8 (0) 2.7 (9)
Valeric acid <0.65 (0) NT <0.65 (0) <0.65 (0) <0.65 (0) <0.65 (0) <0.65 (0) <0.55 (0)
pH 6.7 [6.4–7.4] (100) 5.5 [5.3–6.0] (100) 6.3 [6.0–6.9] (100) 5.4 [5.3–6.4] (100) 6.4 [6.1–6.7] (100) 5.6 [5.5–5.6]*** (100) 6.0 [5.6–6.3] (100)
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tion [22]. An earlier recovery of intestinal function is fa-
vorable, as it might prevent the malnutrition frequently
observed in neonates presenting with congenital heart
disease [5].
We used a B. breve strain Yakult as the probiotic, which
is naturally resistant to cefazolin, an antimicrobial often
used for surgical prophylaxis, and obtained significant
recovery in fecal samples. Moreover, several clinical
studies have shown its beneficial effects in children
[15-17]. Kitajima et al. found that the early administra-
tion of B. breve significantly improved the function of
the digestive tract and promoted weight gain in neonates
[15]. Wada et al. observed a lower incidence of fever and
fewer days of parenteral antimicrobial therapy in patients
undergoing chemotherapy for pediatric malignancies [16].
Those indicate that the use of B. breve strain Yakult could
be a possible option for perioperative use of neonatal heart
surgery.
Limitations
The cardiac anomaly tended to differ among the groups.
Group B contains more arch anomalies including inter-
rupted aortic arch or hypoplastic left heart syndrome.
Since arch anomalies might tend to cause intestinal ische-
mia and associated clinical morbidities, this difference
might be contributed to clinical outcomes, rather than
the administration of probiotics. The risk-adjusted con-
genital heart surgery (RACHS) categories, which represent
surgical complexity and associated outcomes, however,
were similar between the groups (Table 1).
Conclusions
While our observations suggest improvements in gut
function conferred by the administration of B. breve, it
was insufficient to draw any significant conclusions regard-
ing its effect on the incidence of postoperative complica-
tions including infection or postoperative recovery. This
might be inherent due to the nature of pilot study with
small sample size. The clinical benefits of this intervention
remain to be confirmed in larger, future trials.
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